Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Ear Nose Throat J ; : 1455613231223355, 2024 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-38380620

RESUMO

Objective: To analyze the effects of lingual frenotomy on adults with restrictive ankyloglossia and difficult direct laryngoscopy exposure. Methods: A case series study was conducted. Restriction of tongue protrusion due to ankyloglossia was identified in 2 patients who had a history of suboptimal true vocal fold (TVF) exposure on direct laryngoscopy for phonomicrosurgery. Inadequate exposure of the vocal folds was achieved on direct laryngoscopy attempts with manual tongue protrusion. Mandibular tori were not present in these patients. An intraoperative lingual frenotomy was performed in both patients. Results: After frenotomy and with manual tongue protrusion, direct laryngoscopy exposure was substantially improved allowing for considerably more visualization of the anterior TVFs. Conclusion: Lingual frenulum procedures with manual tongue protrusion should be considered in select adult patients with restrictive ankyloglossia affecting optimal direct laryngoscopy exposure.

2.
Medicina (B Aires) ; 82(6): 822-829, 2022.
Artigo em Espanhol | MEDLINE | ID: mdl-36571519

RESUMO

INTRODUCTION: Different COVID-19 vaccines were developed in a short time after the beginning of pandemics, reducing mortality, especially in high risk population. This was demonstrated in several studies, mostly retrospective or based in mathematical models. The objective was to compare mortality in inpatients with COVID-19 related to vaccination. METHODS: Longitudinal, prospective, comparative, observational study. Inpatients with COVID-19 diagnosis were included between 17/12/2021 and 23/02/22, in Hospital Nacional Prof. A Posadas and Hospital Interzonal General de Agudos Eva Perón. RESULTS: Inpatients (245) were analyzed, finding an overall mortality of 25.3%, 16.8% in fully vaccinated patients (two or more doses with less than 150 days since the last dose until the COVID-19 test) and 31.9% in those with incomplete vaccination (unvaccinated, one dose or two or more doses with more than 150 days since the last dose) (p = 0.007), OR 2.31 (IC95; 1.25-4.28) for incomplete vaccination. Mortality was 32.2% in patients who developed pneumonia, 22.2% for fully vaccinated and 38% for incompletely vaccinated (p = 0.048), OR 2.15(IC95; 1.01-4.58). Mortality was associated with older age (70 vs. 59 years; p < 0.001), female sex (54.8% vs. 37.7%; p < 0.02) and oncologic disease (27.4 vs. 14.8%; p = 0.02). PESI score was higher in incompletely vaccinated (102.5 vs. 93, p = 0.05) and SOFA score was lower (2 vs. 3, p = 0.01). The necessary number to treat (NNT) to prevent one death was 7 patients for the overall sample (IC95;4-22) and 6 (IC95;3-106) for pneumonia. DISCUSSION: This study constitutes a starting point for developing other investigations and raising awareness of medical community and people about the beneficial effects of vaccination.


Introducción: Luego del inicio de la pandemia por COVID-19, se desarrollaron diferentes vacunas, disminuyendo la mortalidad según estudios retrospectivos o con modelos de cálculo. El objetivo fue comparar la mortalidad de pacientes internados con diagnóstico de COVID-19 según su vacunación. Métodos: Estudio comparativo observacional longitudinal. Se incluyeron pacientes internados con COVID-19 del 17/12/21 al 23/02/2022 en el Hospital Nacional Prof. A Posadas y en el Hospital Interzonal General de Agudos Eva Perón. Resultados: Se analizaron 245 pacientes hallando una mortalidad total del 25.3%, 16.8% en aquellos con vacunación completa (2 dosis o más y menos de 150 días desde la última) y 31.9% con vacunación incompleta (no vacunados, 1 o 2 dosis y más de 150 días desde la última) (p = 0.007), OR 2.31(IC95; 1.25-4.28). En aquellos con neumonía, la mortalidad fue del 32.2%, 22.2% con vacunación completa y 38% con vacunación incompleta (p = 0.048), OR 2.15(IC95; 1.01-4.58. La mortalidad se asoció a mayor edad (70 vs. 59 años; p < 0.001), sexo femenino (54.8% vs. 37.7%; p < 0.02) y enfermedad oncológica (27.4 vs. 14.8%; p = 0.02). El PESI score fue mayor en aquellos con vacunación incompleta (102.5 vs. 93, p = 0.05) y el SOFA score fue menor (2 vs. 3, p = 0.01). El número necesario a tratar (NNT) para evitar una muerte fue de 7 pacientes para el total de la muestra (IC95; 4-22) y 6 (IC95;3-106) para aquellos con neumonía. Discusión: Este trabajo constituye un punto de partida de nuevas investigaciones, contribuyendo a la concientización acerca de los efectos beneficiosos de la vacunación en profesionales y pacientes.


Assuntos
COVID-19 , Pacientes Internados , Humanos , Feminino , COVID-19/prevenção & controle , Pandemias , Vacinas contra COVID-19 , Teste para COVID-19 , Estudos Prospectivos , Estudos Retrospectivos , Vacinação
3.
Medicina (B.Aires) ; 82(6): 822-829, dic. 2022. graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1422075

RESUMO

Resumen Introducción: Luego del inicio de la pandemia por COVID-19, se desarrollaron diferentes vacunas, disminuyendo la mortalidad según estudios retrospectivos o con modelos de cálculo. El objetivo fue comparar la mortalidad de pacientes internados con diagnóstico de COVID-19 según su vacunación. Métodos: Es tudio comparativo observacional longitudinal. Se incluyeron pacientes internados con COVID-19 del 17/12/21 al 23/02/2022 en el Hospital Nacional Prof. A Posadas y en el Hospital Interzonal General de Agudos Eva Perón. Resultados: Se analizaron 245 pacientes hallando una mortalidad total del 25.3%, 16.8% en aquellos con vacu nación completa (2 dosis o más y menos de 150 días desde la última) y 31.9% con vacunación incompleta (no vacunados, 1 o 2 dosis y más de 150 días desde la última) (p = 0.007), OR 2.31(IC95; 1.25-4.28). En aquellos con neumonía, la mortalidad fue del 32.2%, 22.2% con vacunación completa y 38% con vacunación incompleta (p = 0.048), OR 2.15(IC95; 1.01-4.58. La mortalidad se asoció a mayor edad (70 vs. 59 años; p < 0.001), sexo femenino (54.8% vs. 37.7%; p < 0.02) y enfermedad oncológica (27.4 vs. 14.8%; p = 0.02). El PESI score fue mayor en aquellos con vacunación incompleta (102.5 vs. 93, p = 0.05) y el SOFA score fue menor (2 vs. 3, p = 0.01). El número necesario a tratar (NNT) para evitar una muerte fue de 7 pacientes para el total de la muestra (IC95; 4-22) y 6 (IC95;3-106) para aquellos con neumonía. Discusión: Este trabajo constituye un punto de partida de nuevas investigaciones, contribuyendo a la concientización acerca de los efectos beneficiosos de la vacunación en profesionales y pacientes.


Abstract Introduction: Different COVID-19 vaccines were developed in a short time after the beginning of pandemics, reducing mortality, especially in high risk population. This was demonstrated in several studies, mostly retrospective or based in mathematical models. The objective was to compare mortality in inpatients with COVID-19 related to vaccination. Methods: Longitudinal, prospective, comparative, observational study. Inpatients with COVID-19 diagnosis were included between 17/12/2021 and 23/02/22, in Hospital Nacional Prof. A Posadas and Hospital Interzonal General de Agudos Eva Perón. Results: Inpatients (245) were analyzed, finding an overall mortality of 25.3%, 16.8% in fully vaccinated patients (two or more doses with less than 150 days since the last dose until the COVID-19 test) and 31.9% in those with incomplete vaccination (unvaccinated, one dose or two or more doses with more than 150 days since the last dose) (p = 0.007), OR 2.31 (IC95; 1.25-4.28) for incomplete vaccination. Mortality was 32.2% in patients who developed pneumonia, 22.2% for fully vaccinated and 38% for incompletely vaccinated (p = 0.048), OR 2.15(IC95; 1.01-4.58). Mortality was associated with older age (70 vs. 59 years; p < 0.001), female sex (54.8% vs. 37.7%; p < 0.02) and oncologic disease (27.4 vs. 14.8%; p = 0.02). PESI score was higher in incompletely vaccinated (102.5 vs. 93, p = 0.05) and SOFA score was lower (2 vs. 3, p = 0.01). The necessary number to treat (NNT) to prevent one death was 7 patients for the overall sample (IC95;4-22) and 6 (IC95;3-106) for pneumonia. Discussion: This study constitutes a starting point for develop ing other investigations and raising awareness of medical community and people about the beneficial effects of vaccination.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...